{
    "nctId": "NCT03009058",
    "briefTitle": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer",
    "officialTitle": "A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic or unresectable cancer and considered by their physician to be indicated for a new line of SOC as listed in the protocol\n* Are ineligible for a disease specific clinical study with IMM-101\n* Have an estimated life expectancy greater than 3 months (from Day 0)\n* Give signed informed consent for participation in the study\n* Have an Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) Performance Status of \u22642 at Day 0.\n* Have adequate bone marrow, hepatic and renal function\n\nExclusion Criteria:\n\n* Patient has previously received treatment with IMM-101\n* Patient is currently part way through a course of chemotherapy or immunotherapy\n* Patient is receiving concomitant treatment with another investigational product\n* Patient has received an investigational drug within the 4 weeks prior to IMM 101 administration\n* Patient has significant cardiovascular disease\n* Patient has any previous or concurrent malignancy (excluding adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin and/or non melanoma skin cancer, or if previous malignancy was more than 5 years prior to Screening and there are no signs of recurrence)\n* Patient has co existing active infection or medical condition which will substantially increase the risk associated with the patient's participation in the study\n* Patient has uncontrolled hypercalcaemia\n* Patient has previously experienced an allergic reaction to any mycobacterial product.\n* The patient has a history of non-infectious pneumonitis that required steroids or current pneumonitis\n* Patient has received live vaccine within 30 days of planned start of study medication\n* Patient is pregnant or a breast feeding woman.\n* Patient is unwilling to use a medically acceptable, effective method of contraception throughout the treatment period and for at least 6 months after discontinuation of treatment.\n* Patient has used depot corticosteroids in the 6 weeks before initiation of Screening\n* Patient has had chronic use of systemic corticosteroids within the 2 week period before the first administration of IMM-101\n* Patient has received a blood transfusion within 4 weeks prior to Screening\n* In the opinion of the Investigator, the patient is unable or unwilling to comply with the protocol.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}